Please login to the form below

Not currently logged in
Email:
Password:

Lipoxen collaboration with Pharmasynthez

UK-based biopharma group, Lipoxen, has announced a collaboration deal with Russian, research-based pharma company, Pharmasynthez ZAO
The collaboration allows Pharmsynthez to apply Lipoxen's ImuXen and PolyXen proprietary technologies to a broad range of six drug and vaccine candidates.  

The aim is to create three enhanced vaccine candidates for secondary progressive multiple sclerosis (MS), HIV and non-Hodgkin's lymphoma and three pharmaceutical candidates for treatment of cystic fibrosis, acute myeloid leukaemia, non-Hodgkin's lymphoma and type 2 diabetes.

As a result of the agreement, Lipoxen will receive royalties of 10 per cent of all net sales from Pharmsynthez, should the products progress through clinical development and be approved for marketing in the Russian Federation. Any arising intellectual property will be jointly owned by the two parties, unless it relates solely to Lipoxen's platform technologies.

Pharmsynthez will optimise the candidates with guidance from Lipoxen and will complete testing to achieve clinical proof of principle by the end of 2010. Candidates that show promise will then progress to full-scale clinical development in Europe and the US.

Operating from the UK, Lipoxen develops high-value, differentiated pharmaceutical products in the areas of protein drugs, vaccines and anti-cancer drugs. The company was founded by Professor Gregory Gregoriadis, PhD, DSc, in 1997, as a spin-off from The School of Pharmacy at the University of London. In January 2006 Lipoxen became a London Stock Exchange AIM-listed company.

16th November 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics